Sims, Charles R.
Bressler, Adam M.
Graham, Donald R.
Lacy, Melinda K.
Lombardi, David A.
Castaneda-Ruiz, Bibiana
Clinical trials referenced in this document:
Documents that mention this clinical trial
Clinical Experience with Telavancin for the Treatment of Patients with Bacteremia and Endocarditis: Real-World Results from the Telavancin Observational Use Registry (TOUR™)
https://doi.org/10.1007/s40801-020-00191-x
Real-World Clinical Use and Outcomes of Telavancin for the Treatment of Bone and Joint Infections: Results from the Telavancin Observational Use Registry (TOUR™)
https://doi.org/10.1007/s40801-021-00255-6
Funding for this research was provided by:
Theravance Biopharma US
Article History
Accepted: 23 April 2021
First Online: 26 May 2021
Declarations
:
: This study was funded by Theravance Biopharma R&D, Inc.
: Charles R. Sims has received research support and speaker honoraria from Theravance Biopharma R&D, Inc. Adam M. Bressler has received fees for participating in advisory boards and speaker bureaus for Theravance Biopharma R&D, Inc. Donald R. Graham has received grants or research support from Apex Bioscience, Aronex, Inc., Arpida, Artisan Pharmaceutical, Astra Zeneca, Aventis, Basilea, Inc., Bayer Corp., Biocryst, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, CEM-102, Centocor, Cerexa, Chiron, Inc., Cubist, Inc., Forest Pharmaceuticals, Genomics, Gilead, GlaxoSmithKline, Incyte Corp., InsMed, Johnson & Johnson, Liposomal Company, Inc., The Medicines Company, Merck & Co., Miles Pharmaceuticals, Novartis Pharmaceuticals, Optimer Pharmaceuticals, Ortho-McNeil, Parke-Davis, Peninsula Pharmaceuticals, Pfizer, Rib-X, Roche Pharmaceuticals, R. W. Johnson, Inc., Salix Pharmaceuticals, Sanofi Pasteur, Schering-Plough, Sequus, Inc., Serono, Targanta, Theravance Biopharma R&D, Inc., Tibotec, Trius Therapeutics, Vertex, and Xoma Corp., and consulting fees from Bristol-Myers Squibb, City of Springfield, Oscient Pharmaceuticals, Memorial Medical Center, Illinois Department of Human Services, Division of Mental Health, Rhone-Poulenc Rorer, Saint John’s Hospital, Sangamon County Department of Public Health, Illinois, Vibra Hospital, Springfield, and various home care programs, nursing homes, and tuberculosis programs. Melinda K. Lacy and David A. Lombardi DL and ML are employees of Theravance Biopharma US, Inc., and may hold stock. Bibiana Castaneda-Ruiz is a former employee of Theravance Biopharma US, Inc., and may hold stock.
: The Copernicus Group Independent Review Board approved the TOUR observational study protocol on 29 December, 2015.
: This was an observational use study with data collected via retrospective medical chart reviews, therefore signed informed consent from the patient was not required. Only de-identified information was collected in accordance with Section 164.514 of the Health Insurance Portability and Accountability Act Privacy Rule.
: Not applicable.
: Cumberland Pharmaceuticals Inc. (and its affiliates) will not be sharing individual de-identified patient data or other relevant study documents.
: Not applicable.
: All authors reviewed, read, and approved the final manuscript. BC and ML provided critical analysis of the data and were major contributors. CS, AB, and DG were investigators who contributed patient data to TOUR and provided a critical analysis of the data. DL performed the statistical analysis.